NKTX Nkarta, Inc.

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates include NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.

$13.16  +0.84 (6.82%)
As of 07/01/2022 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/11/2020
Outstanding shares:  33,009,594
Average volume:  753,579
Market cap:   $396,775,320
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BK80YJ8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.78
PS ratio:   0.00
Return on equity:   -40.53%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy